As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new analysis finds a large majority of Canadian groups that submitted comments about pending government coverage for medicines also held conflicts with drug makers.

Specifically, 87 percent of comments were made by Canadian groups that had a conflict of interest, such as industry backing. And of those comments, 86 percent involved a conflict with the drug maker that was marketing the medicine being reviewed by the Common Drug Review and panCanadian Oncology Drug Review. These agencies make recommendations to provincial and federal drug plans about funding coverage.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy